FDA Questions CV Events, Small Database Heading Into Aclidinium Bromide Advisory Committee
This article was originally published in The Pink Sheet Daily
You may also be interested in...
Forest Laboratories’ sales representatives will combine marketing for aclidinium, which FDA approved July 24, with their education efforts for Daliresp for COPD exacerbations.
The twice-daily aclidinium, a long-acting antimuscarinic agent, should be available to wholesalers in the fourth quarter.
Pulmonary-Allergy Drugs Advisory Committee members say post-marketing study is necessary, and Forest has already made a preliminary proposal.